Aurobindo Pharma Limited — PPTs, 26-05-2025: Investor Presentation

1. Financial Highlights:

Aurobindo Pharma posted record revenues of ₹8,382 Cr, up 5.1% QoQ and 10.6% YoY. EBITDA rose to ₹1,792 Cr with a margin of 21.4%, driven by better gross margins near 59% and operational efficiencies. Net profit was ₹903 Cr, up 6.7% QoQ but flat YoY. Overheads increased 4.2% QoQ. The company improved its position to a net cash balance of ~US$42 million from net debt last quarter. The US formulation market remains the key growth engine, delivering US$470 million (+8% QoQ, +9% YoY), nearly half of total sales.

2. Strategic Initiatives & Growth Drivers:

Capex of US$90 million was directed toward capacity expansion and new business areas. R&D investment stood at ₹423 Cr to support pipeline growth. The biosimilars division is scaling up, expanding bioreactor capacity and preparing for multiple product submissions, including its first US FDA filing targeted for FY26. The company maintained an aggressive ANDA filing pace in the US with 9 filings and 5 approvals this quarter.

3. Business Developments:

Aurobindo introduced 5 new products in the US this quarter. Biosimilars made significant progress with approvals from EC and MHRA, and Phase 3 trials ongoing for candidates like biosimilars of Xolair, Prolia, and Avastin. Plans are underway to supply biosimilars to the EU by FY26, strengthening its differentiated biologics portfolio.

4. Market Position & Competitive Advantage:

Strong scale in the US market backed by consistent ANDA filings and approvals bolsters the pipeline. Europe grew 16% YoY and ARV segment 24% YoY, adding diversification. The integrated API-to-formulation platform, expanding biosimilars pipeline, and cost efficiencies add to Aurobindo’s competitive strengths.

5. Investor Implications:

Robust execution and strong pipeline investments suggest positive growth potential. Improved cash flow and deleveraging offer balance sheet flexibility. Investors should watch commercial execution of biosimilars and regulatory milestones in the US. Overall, Aurobindo shows resilience and diversified growth across key segments.